Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Other financing activities: 2017-2024

Historic Other financing activities for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $26.5 million.

  • Protagonist Therapeutics' Other financing activities fell 53.04% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 6.96%. This contributed to the annual value of $26.5 million for FY2024, which is 454.11% up from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Other financing activities is $26.5 million, which was up 454.11% from $4.8 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Other financing activities registered a high of $26.5 million during FY2024, and its lowest value of $2.8 million during FY2020.
  • In the last 3 years, Protagonist Therapeutics' Other financing activities had a median value of $4.8 million in 2023 and averaged $11.9 million.
  • Its Other financing activities has fluctuated over the past 5 years, first decreased by 29.21% in 2022, then spiked by 454.11% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Other financing activities (Yearly) stood at $2.8 million in 2020, then soared by 124.47% to $6.3 million in 2021, then decreased by 29.21% to $4.4 million in 2022, then grew by 7.33% to $4.8 million in 2023, then soared by 454.11% to $26.5 million in 2024.